Amarantus Bioscience Holdings Inc (AMBS)

[Disney714]

Amarantus will pump into Hermo Pharma at the European Neurotech Investing and Partnering Summit 2013 in September
Looks like they can be friend, which is good IMHO

http://www.regonline.com/builder/site/tab1.aspx?EventID=1151412

Gerald Commissiong, President & CEO, Amarantus Bioscience
12:30 Lunch

Keynote: Juhani Lahdenperä, CEO, Hermo Pharma

In the past, Hermo Pharma had sued AMBS for the MANF patent.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82939414

Ties between GDNF, MANF and Hermo Pharma

(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family

(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants

(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:www.hermopharma.com/about-us/scientific-advisory-board

(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins

(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion
device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html

(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents
cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity)
to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.

(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.

(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.